Adaptive Biotechnologies Highlights clonoSEQ Growth, 2026 Cash Flow Goal at Conference

Adaptive Biotechnologies NASDAQ: ADPT Chief Executive Officer and Co-Founder Chad Robins said the company is focused on expanding its minimal residual disease testing business while pursuing targeted partnerships for its Immune Medicine platform, during a presentation at William Blair's Growth Stock Conference.